These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32830821)

  • 1. Modeling the Puzzle of Hepatitis C Epidemiology in Romania: A Pathway to Control.
    Lopes H; Baptista-Leite R; Franco D; Eclemea I; Bratu EC; Furtunescu FL; Pop CS; Pana BC
    J Gastrointestin Liver Dis; 2020 Sep; 29(3):377-384. PubMed ID: 32830821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Let's End HepC: Modelling Public Health Epidemiological Policies Applied to Hepatitis C in Spain.
    Lopes H; Baptista-Leite R; Franco D; Serra MA; Escudero A; Martín-Moreno JM
    Front Public Health; 2021; 9():735572. PubMed ID: 35071151
    [No Abstract]   [Full Text] [Related]  

  • 3. Integrating public health policies in the epidemiological modeling of hepatitis C with LEHC tool: application in Austria.
    Lopes H; Baptista-Leite R; Franco D; Pirker R; Gschwantler M
    Wien Klin Wochenschr; 2021 May; 133(9-10):461-469. PubMed ID: 33331968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiological Modeling of the Impact of Public Health Policies on Hepatitis C: Protocol for a Gamification Tool Targeting Microelimination.
    Baptista-Leite R; Lopes H; Vandewalle B; Félix J; Franco D; Clemens T; Brand H
    JMIR Res Protoc; 2023 Sep; 12():e38521. PubMed ID: 37747764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prevalence of HCV Infection and Risk Factors in a Hospital- Based Population Screening, a First Step to the Micro-Elimination of HCV Infection in Medical Institutions from Romania - Results of the HepC ALERT Study.
    Gheorghe L; Iacob S; Csiki IE; Huiban L; Cojocaru M; Cojocariu C; Nemteanu R; Girleanu I; Sirli R; Singeap AM; Pop C; Dumitrascu DL; Vadan R; Iacob R; Diculescu M; Trifan A; Sporea I; Gheorghe C
    J Gastrointestin Liver Dis; 2020 Dec; 29(4):587-593. PubMed ID: 33331354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Seroprevalence Study of Hepatitis B and C Virus Infections in a Hospitalized Population in Romania, an Opportunity for a Better National Prevention and Control Strategy.
    Popovici O; Molnar GB; Popovici F; Janţă D; Pistol A; Azoicăi D
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):25-32. PubMed ID: 27014751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings.
    Scott N; Sacks-Davis R; Pedrana A; Doyle J; Thompson A; Hellard M
    J Viral Hepat; 2018 Dec; 25(12):1472-1480. PubMed ID: 30047625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
    Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
    Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral hepatitis in Bucharest.
    Paquet C; Babes VT; Drucker J; Sénémaud B; Dobrescu A
    Bull World Health Organ; 1993; 71(6):781-6. PubMed ID: 8313496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006 - 2008.
    Gheorghe L; Csiki IE; Iacob S; Gheorghe C; Smira G; Regep L
    J Gastrointestin Liver Dis; 2010 Dec; 19(4):373-9. PubMed ID: 21188327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
    European Union HCV Collaborators
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cross-sectional epidemiological study of HBV, HCV, HDV and HEV prevalence in the SubCarpathian and South-Eastern regions of Romania.
    Voiculescu M; Iliescu L; Ionescu C; Micu L; Ismail G; Zilisteanu D; Radasan A; Micu G; Pertache I
    J Gastrointestin Liver Dis; 2010 Mar; 19(1):43-8. PubMed ID: 20361074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.
    Cornberg M; Razavi HA; Alberti A; Bernasconi E; Buti M; Cooper C; Dalgard O; Dillion JF; Flisiak R; Forns X; Frankova S; Goldis A; Goulis I; Halota W; Hunyady B; Lagging M; Largen A; Makara M; Manolakopoulos S; Marcellin P; Marinho RT; Pol S; Poynard T; Puoti M; Sagalova O; Sibbel S; Simon K; Wallace C; Young K; Yurdaydin C; Zuckerman E; Negro F; Zeuzem S
    Liver Int; 2011 Jul; 31 Suppl 2():30-60. PubMed ID: 21651702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
    Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
    PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C transmission and treatment as prevention - The role of the injecting network.
    Hellard M; McBryde E; Sacks Davis R; Rolls DA; Higgs P; Aitken C; Thompson A; Doyle J; Pattison P; Robins G
    Int J Drug Policy; 2015 Oct; 26(10):958-62. PubMed ID: 26072105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the way to Hepatitis C elimination in the Republic of Georgia-Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study.
    Chikovani I; Ompad DC; Uchaneishvili M; Sulaberidze L; Sikharulidze K; Hagan H; Van Devanter NL
    PLoS One; 2019; 14(4):e0216123. PubMed ID: 31034530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.
    Cousien A; Leclerc P; Morissette C; Bruneau J; Roy É; Tran VC; Yazdanpanah Y; Cox J
    BMC Infect Dis; 2017 Feb; 17(1):162. PubMed ID: 28222681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication.
    Leask JD; Dillon JF
    Aliment Pharmacol Ther; 2016 Jul; 44(2):145-56. PubMed ID: 27199103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepcare Europe - bridging the gap in the treatment of hepatitis C: study protocol.
    Swan D; Cullen W; Macias J; Oprea C; Story A; Surey J; Vickerman P; Lambert JS
    Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):303-314. PubMed ID: 29300496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.